The molecular landscape and associated clinical experience in infant medulloblastoma: prognostic significance of second-generation subtypes.

D HicksG RafieeE C SchwalbeC I HowellJ C LindseyR M HillA J SmithP AdidharmaC SteelS RichardsonL PeaseM DanilenkoS CrosierA JoshiStephen B Wharton Thomas S JacquesB PizerA MichalskiD WilliamsonS BaileySteven C Clifford

Published in: Neuropathology and applied neurobiology (2020)

Investigations of large, retrospective cohorts have enabled the comprehensive and robust characterization of molecular heterogeneity within iMB. Novel subtypes are clinically significant and subgroup-dependent survival models highlight opportunities for biomarker-directed therapies.

Keyphrases

single cell
single molecule
randomized controlled trial
clinical trial
study protocol